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Inter-individual variability in oral drug efficacy and toxicity is
commonly observed in all therapeutic areas. Importantly, inter-
individual variability in drug uptake and metabolism can result
in poor drug response, adverse drug reactions, or unfavorable
drug–drug interaction. One of the common causes of indi-
vidual variations in drug response is genetic variation of drug
transporters and metabolizing enzymes [1,2].We focus on the
interplay between efflux transporter (ATP-binding cassette, sub-
family B (MDR/TAP), member 1/ABCB1) and cytochrome P450s
according to genetic polymorphism [3]. The objective of this
lecture is to investigate the combined influence of genetic poly-
morphisms in ABCB1 and CYP2D6 genes on risperidone
pharmacokinetics [4].
Eighty healthy subjects who received a single oral dose of
2 mg risperidone participated in this study.We conducted the
population pharmacokinetic analysis of risperidone and
9-hydroxyrisperidone using a nonlinear mixed effects mod-
eling (NONMEM) method and explored the possible influence
of genetic polymorphisms in CYP2D6 alleles and ABCB1
(2677G > T/A and 3435C > T) on the population pharmacoki-
netics of risperidone and 9-hydroxyrisperidone.
Significant differences were observed between the ABCB1
3435C > T genotypes for the pharmacokinetic parameters (Cmax)
of risperidone and the active moiety (risperidone and its main
metabolite, 9-hydroxyrisperidone).There were no significant dif-
ferences in theAUC of risperidone and the active moiety among
the ABCB1 2677G > T/A and 3435C > T genotypes. However, the
Cmax andAUCwere significantly different (P < 0.001 and P = 0.002
for risperidone, and P = 0.018 and P = 0.038 for the active moiety)
among ABCB1 3435C > T genotypes in CYP2D6*10/*10.
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A two-compartment model with a first-order absorption and
lag time fitted well to serum concentration–time curve for
risperidone. 9-hydroxyrisperidone was well described by a one-
compartment model as an extension of the parent drug
(risperidone) model with first-order elimination and absorp-
tion partially from the depot. Significant covariates for
risperidone clearance were genetic polymorphisms of
CYP2D6*10, including CYP2D6*1/*10 (27.5% decrease) and
CYP2D6*10/*10 (63.8% decrease). There was significant differ-
ence in the absorption rate constant (ka) of risperidone among
the CYP2D6*10 genotype groups. In addition, combined ABCB1
3435C > T and CYP2D6*10 genotypes had a significant (P < 0.01)
effect on the fraction of metabolite absorbed from the depot.
The population pharmacokinetic model of risperidone and
9-hydroxyrisperidone including the genetic polymorphisms of
CYP2D6*10 and ABCB1 3435C > T as covariates was success-
fully constructed [4].
Fig. 1 illustrates a summary of the interplay of CYP2D6 and
ABCB1 at enterocytes on the pharmacokinetics of risperidone
and 9-hydroxyrisperidone according to genetic polymorphisms
and indicates that the interplay has an important physiologi-
cal role as “a functional barrier”, pumping out not only parent
drug, but also metabolites generated in the enterocytes.The es-
timated contribution of genetic polymorphisms in CYP2D6*10
and ABCB1 3435C > T to population pharmacokinetics of
risperidone and 9-hydroxyrisperidone suggests the interplay of
CYP2D6 andABCB1 on the pharmacokinetics of risperidone and
9-hydroxyrisperidone according to genetic polymorphisms.These
findings indicate that polymorphisms of ABCB1 3435C > T in in-
dividuals with CYP2D6*10/*10, which has lowmetabolic activity,
could play an important role in the potential adverse effects or
toxicity of risperidone [4].
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Fig. 1 – Hypothetical interplay of P-gp and CYP enzymes
according to genetic polymorphisms in the enterocytes.
UM, ultra-metabolizers; EM, extensive metabolizers; IM,
intermediate metabolizers; PM, poor metabolizers (cited
from Reference [3]).
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